Long-term safety follow-up for cadonilimab study participants
Part of Cancer, Digestive system clinical trials.
This is a follow-up study for people who previously received cadonilimab (AK104), an experimental cancer drug, in an earlier clinical trial. Researchers will check in with you periodically to monitor your health and collect information about how you're doing long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You participated in a previous cadonilimab (AK104) clinical trial run by Akeso
- You completed or finished that earlier trial
- You can read, understand, and sign consent forms
- You agree to participate in follow-up visits and health checks
- You can participate in other clinical studies at the same time if you choose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
This trial tests if adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery can help treat stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this combination improves outcomes for patients.
This study tests whether adding cadonilimab (and possibly AK117) to chemotherapy can improve outcomes for people with resectable stomach or stomach–esophagus cancer. It aims to see if this combination works better than chemotherapy alone, while still being safe around surgery.
This trial tests a drug called cadonilimab in women with cervical cancer that has returned or spread. The goal is to see how well it works in real life and to help manage the cancer.
This trial tests a new immunotherapy drug called cadonilimab for women with cervical cancer that has returned, spread, or is advanced. The goal is to see if it works well, how safe it is, and if it costs less than standard treatments.
Hear when a new Locally Advanced Unresectable or Metastatic Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.